Neumora Therapeutics is pressing forward with an NLRP3 inhibitor program for obesity after competitors failed to deliver weight‑loss efficacy. Preclinical data released by the company show that its brain‑penetrant oral NLRP3 inhibitor NMRA‑215 produced weight loss in mice, supporting further development as monotherapy and in combination with GLP‑1 agonists. Neumora’s strategic move come amid shifting investor interest in neuroscience companies entering metabolic indications. The company argues that targeting central inflammatory pathways such as NLRP3 could complement appetite‑suppressing GLP‑1 drugs and address mechanisms not reached by existing agents. Preclinical efficacy will need to translate into clinical benefits in humans; Neumora plans to advance its candidate into formal toxicology and IND‑enabling studies.